Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

NCT02781883 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: BP1001 in combination with Ventoclax plus decitabine
DRUG: BP1001 plus decitabine

Sponsor

Bio-Path Holdings, Inc.